Department of Ophthalmology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, China.
Key Laboratory of Ocular Fundus Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Graefes Arch Clin Exp Ophthalmol. 2021 Apr;259(4):883-889. doi: 10.1007/s00417-020-04983-3. Epub 2020 Nov 18.
To evaluate choroid thickness and macular retinal metrics in treatment naïve retinal vein occlusion (RVO) patients with serous retinal detachment (SRD) before and after intravitreal anti-vascular endothelial cell growth factor (VEGF) injection and to elucidate the possible role of choroid in the development of SRD and the potential role of SRD as a prognostic parameter.
This is a retrospective study involving 85 RVO patients, 41 central retinal vein occlusion (CRVO), and 44 branch retinal vein occlusion (BRVO), with macular edema: 21 central retinal vein occlusion and 22 branch retinal vein occlusion with SRD and the rest without SRD. Patients were evaluated with ophthalmic examinations and swept-source optical coherence tomography (SS-OCT) both before and 4-6 weeks after intravitreal anti-VEGF treatment. Choroid thickness and retinal metrics were measured and compared between SRD and non-SRD groups within each RVO subtype.
In both CRVO and BRVO patients, the mean central subfield foveal thickness (CSFT) and central subfoveal choroid thickness (CSCT) of the SRD groups were thicker than those in the non-SRD groups (p < 0.05) at onset. After one anti-VEGF injection, CSFT and FNRT decreased in all groups (p < 0.05). The CSCTs were thicker in the SRD groups compared with the non-SRD groups (p < 0.05). The mean changes of CSFT were more remarkable in the SRD groups (p < 0.05).
Thicker choroid was a feature of naïve RVO patients with SRD and SRD may be an indicator of better anatomical recovery of retina in RVO patients after a single dose of anti-VEGF treatment.
评估未经治疗的视网膜静脉阻塞（RVO）合并浆液性视网膜脱离（SRD）患者在玻璃体内抗血管内皮生长因子（VEGF）注射前后脉络膜厚度和黄斑视网膜参数，并阐明脉络膜在 SRD 发展中的可能作用以及 SRD 作为预后参数的潜在作用。
这是一项回顾性研究，共纳入 85 例 RVO 患者，其中 41 例为中央视网膜静脉阻塞（CRVO），44 例为分支视网膜静脉阻塞（BRVO），伴有黄斑水肿：21 例为中央视网膜静脉阻塞，22 例为分支视网膜静脉阻塞伴 SRD，其余为无 SRD。所有患者均接受眼科检查和扫频源光学相干断层扫描（SS-OCT）检查，分别在玻璃体内抗 VEGF 治疗前和 4-6 周后进行。在每个 RVO 亚型中，比较 SRD 和非 SRD 组之间的脉络膜厚度和视网膜参数。
在 CRVO 和 BRVO 患者中，SRD 组的中央凹视网膜神经纤维层厚度（CSFT）和中央凹脉络膜厚度（CSCT）在发病时均比非 SRD 组厚（p<0.05）。一次抗 VEGF 注射后，所有组的 CSFT 和 FNRT 均降低（p<0.05）。SRD 组的 CSCT 比非 SRD 组厚（p<0.05）。SRD 组 CSFT 的平均变化更显著（p<0.05）。
未经治疗的 RVO 合并 SRD 患者的脉络膜较厚，单次抗 VEGF 治疗后，SRD 可能是 RVO 患者视网膜解剖学恢复更好的指标。
